 |
|
Lower IQ found in children of women who took epilepsy drug
May 04, 2007BOSTON - Children of women who took the epilepsy drug valproate during pregnancy appear to be at a greater risk for lower IQ, according to research presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 - May 5, 2007.
The study looked at IQ results for 187 two-year-old children of mothers who took the epilepsy drugs carbamazepine, lamotrigine, phenytoin, or valproate during pregnancy.
According to the study, 24 percent of the children of mothers who took valproate showed an IQ in the mental retardation range, compared to 12 percent for carbamazepine, nine percent for lamotrigine, and 12 percent for phenytoin. On an IQ test, children whose mothers took carbamazepine scored an average of 93 points, compared to 93 for those who took phenytoin, 96 for lamotrigine, and 84 for valproate. The scores were adjusted to account for the mother's IQ and the drug dosage.
The study also found that children with higher levels of valproate in their blood had lower IQ scores.
"Further studies are needed to confirm these findings, examine IQ at older ages, and to determine the risks for other epilepsy drugs," said study author Kimford Meador, MD, of the University of Florida in Gainesville, FL, and Fellow of the American Academy of Neurology. "However, our findings are consistent with other studies, which have shown valproate poses an increased risk for fetal death and birth defects, and have suggested the drug may harm cognitive development."
The study also found children's IQ was related to their mother's IQ for every epilepsy drug except valproate.
Meador is recommending doctors talk with their patients about the risks associated with valproate.
"Although valproate remains an important treatment option in women who aren't able to use other epilepsy drugs, valproate should not be used as the drug of first choice for women of child bearing potential, and when used, its dosage should be limited if possible," said Meador.
American Academy of Neurology
The study also found that children with higher levels of valproate in their blood had lower IQ scores.
"Further studies are needed to confirm these findings, examine IQ at older ages, and to determine the risks for other epilepsy drugs," said study author Kimford Meador, MD, of the University of Florida in Gainesville, FL, and Fellow of the American Academy of Neurology. "However, our findings are consistent with other studies, which have shown valproate poses an increased risk for fetal death and birth defects, and have suggested the drug may harm cognitive development."
The study also found children's IQ was related to their mother's IQ for every epilepsy drug except valproate.
Meador is recommending doctors talk with their patients about the risks associated with valproate.
"Although valproate remains an important treatment option in women who aren't able to use other epilepsy drugs, valproate should not be used as the drug of first choice for women of child bearing potential, and when used, its dosage should be limited if possible," said Meador.
American Academy of Neurology
Epilepsy drug may help Alzheimer's patients
A popular epilepsy drug may also be beneficial in patients with Alzheimer's disease (AD), according to a new study to be published on October 27 in the Journal of Experimental Medicine. The anti-seizure drug valproic acid improved memory and reduced brain lesions in mice with an AD-like disease.
Drug monitoring reduces seizures in pregnant women with epilepsy
A popular epilepsy drug taken by pregnant women with epilepsy because of its mild risk of birth defects has been linked to increased seizure activity in up to 75 percent of pregnancies.
Monitoring of a common epilepsy drug during pregnancy reduces seizure risk
Research at Emory University shows that monitoring the level of an epilepsy drug, called lamotrigine, in the blood helps reduce increased seizure activity and improve the overall health of pregnant women and their fetuses.
Epilepsy drug eases symptoms of inherited disorder that weakens muscles
An epilepsy drug that has been on the market for decades can ease the symptoms of adult sufferers with a genetic disorder that seriously weakens muscles.
Economic Evaluation (A UK Evaluation) Shows Add-on Therapy With Keppra® (Levetiracetam) is a Cost-effective Alternative To Maintenance Of Standard Therapy For The Treatment Of Refractory Epilepsy
Belgium (4 April 2003) - New cost-effectiveness data presented today at the American Academy of Neurology (AAN) congress, 29th March-5th April, in Honolulu, Hawaii, USA, shows add-on therapy with Keppra* (levetiracetam) is a cost-effective alternative to standard treatment of refractory epilepsy1. The incremental cost-effectiveness analysis clearly shows that substantial benefits of seizure freedom can be obtained by the addition of Keppra at relatively modest cost1. This news has important implications for the treatment of epilepsy around the world with potentially substantial benefits for patients as well as healthcare budgets. Epilepsy is the most common serious neurological condition, wi
More Epilepsy Drug Current Events and Epilepsy Drug News Articles
 |
The Ketogenic Diet: A Treatment for Children and Others with Epilepsy by M.D. John Freeman (Author), M.D. Eric H. Kossoff (Author), Jennifer B. Freeman (Author), R.D. Millicent T. Kelly (Author) Sometimes called the “miracle diet,” the ketogenic diet has helped doctors treat difficult-to-control epileptic seizures in thousands of children. Coauthored by two respected Johns Hopkins neurologists, The Ketogenic Diet continues to be the definitive guide for parents, physicians, and dieticians wanting to implement this strict diet. This fourth edition is extensively updated to reflect current advances in understanding how the diet works, how it should be used, and the future role of the diet as a treatment. The best-seller also includes sample meal plans, a food database, a section on how the Atkins and modified ketogenic diet can be used as alternative diets to control epilepsy, and much more. |
 |
A Healthy Body & Medicine Answers questions such as "How does the body make blood cells?" "What do veins do?" "What does salt do for the body?" "What is an addict?" It also answers such questions as "Why do we get a fever?" "What are measles?" "What is epilepsy?" What is hay fever This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
MemoCharts Pharmacology: Drug Therapy for Epilepsy (Review chart) by Howard Shen (Author) An integrated mini review of the drug therapy for epilepsy, illustrated with visually appealing tables and diagrams. A quick visual aid for the course study and board review |
 |
The Treatment of Epilepsy by Simon D. Shorvon (Editor), Emilio Perucca (Editor), Jerome Engel Jr. (Editor) A practical reference to the medical and surgical treatment of epilepsy The third edition of The Treatment of Epilepsy has been thoroughly updated. It is a reference work, but has a strong practical bias, and is designed to assist neurologists, neurosurgeons and other clinicians at all levels who are involved in the treatment of patients with epilepsy. It is a definitive source of clinical information to guide clinical practice and rational therapy. Written and edited by leading experts, many actively involved with the International League Against Epilepsy, this new edition: covers the recent advances in the principles and approaches to epilepsy therapy, the introduction of new drugs and the development of new surgical techniques contains 26 completely... |
 |
Drugs for the Control of Epilepsy: Actions on Neuonal Networks Involved in Seizure Networks by Carl L. Faingold (Author), Gerhard H. Fromm (Author) This book brings together the ideas of an international group of experts on clinical and experimental epilepsy. These authors consider how antiepileptic drugs may act on elements of neuronal networks to reduce seizure incidence and severity. The book addresses such topics as the four general classes of anticonvulsant drug mechanisms, major epilepsy models, the proposed mechanisms of action of major antiepileptic drugs, and the clinical use of antiepileptic drugs in the treatment of various forms of human epilepsy. This volume is special for its focus on the neuronal network approach to epilepsy, as well as for its comprehensive review and integration of human and animal data. Neurologists, pharmacologists, psychiatrists, and other investigators actively working on epilepsy research will... |
 |
A Antiepileptic Drugs: A Clinician's Manual (Oxford American Neurology Library) by A Ali Asadi-Pooya (Author), Michael Sperling (Author) Part of the Oxford American Neurology Library, this concise handbook provides practical, up-to-date clinical guidance on effectively selecting, prescribing and monitoring antiepileptic drugs (AEDs), based on drug pharmacokinetics, drug interactions, other uses of AEDs, adverse-effects of AEDs and patient clinical characteristics (i.e. age, comorbidities, and comedications) in partial and generalized epilepsies. This book is designed to provide physicians with a highly patient-focused reference. It provides comprehensive coverage of current treatment options, and in addition to a brief formal discussion of the basic pharmacology of each antiepileptic drug, the text also discusses how to choose pharmacotherapies depending upon underlying medical conditions and the type of epilepsy. The... |
|
Data help prioritize drugs for treating epilepsy.(Neuropsychiatric Medicine)(Clinical report): An article from: Clinical Psychiatry News by Elizabeth Mechcatie (Author) This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on June 1, 2007. The length of the article is 724 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Data help prioritize drugs for treating epilepsy.(Neuropsychiatric Medicine)(Clinical report) Author: Elizabeth Mechcatie Publication: Clinical Psychiatry News (Magazine/Journal) Date: June 1, 2007 Publisher: Thomson Gale Volume: 35 Issue: 6 Page: 38(1) Article Type: Clinical report Distributed by Thomson... | |
 |
New Antiepileptic Drug Development: Preclinical and Clinical Aspects (Epilepsy Research Supplement) by Jacqueline A. French (Author), Marc A. Dichter (Author), Ilo E. Leppik (Author) This volume represents the input of individuals involved in aspects of antiepileptic drug development and discusses how the process can be improved upon and drug evaluation made more effective. Topics range from the theoretical such as ethical issues, to the practical such as study budgets. |
 |
Drug Resistance in Epilepsy: Lessons from Oncology - No. 243 (Novartis Foundation Symposia) by Novartis Foundation (Author) Drug resistance in epilepsy is an important clinical problem. About 200f patients diagnosed as having epilepsy fail to respond to prescribed antiepileptic drugs and continue to have seizures. But despite the size of the problem, remarkably little attention has been paid to the biological basis of refractory epilepsy. Recent work has shown that brain tissue from some patients with epilepsy shows increased expression of a protein that mediates drug resistance in cancer, P glycoprotein. But while resistance in cancer has been extensively studied, and trials of reversal of resistance have been undertaken with some success, resistance in epilepsy has only just begun to be addressed. This novel book brings together, for the first time, epilepsy researchers and oncologists, with a view to... |
|
New Antiepileptic Drugs (Epilepsy Research Supplement) by Francesco Pisani (Author), Emilio Perucca (Author), Giuliano Avanzini (Author), A. Richens (Author) The pharmacological fight against epilepsy began many centuries ago when Hippocrates discovered that the cause of epilepsy is natural, as opposed to supernatural and, as a consequence, must be treated with a natural remedy. Even though science has significantly progressed since that era, the challenge to find remedies for epilepsy is ever present. The aim of this particular volume is to offer an up-to-date review of the most recent advances in antiepileptic drug development, considered from various viewpoints: (i) general, by taking into account the size of refractory epilepsy and its related problems; (ii) experimental, by exploring the mechanisms of epileptogenesis and the possiblility of influencing it through drugs, and (iii) clinical, by describing the results obtained with compounds... |
| © 2009 BrightSurf.com |